The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview
Author:
Publisher
Springer Science and Business Media LLC
Subject
Internal Medicine
Link
http://www.nature.com/articles/1001391.pdf
Reference9 articles.
1. Brunner HR . Olmesartan medoxomil: a new AT1 receptor antagonist for the treatment of hypertension. Introduction J Hypertens 2001 19 (Suppl): S1–S2
2. Koike H, Sada T, Mizuno M . In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist J Hypertens 2001 19 (Suppl): S3–S14
3. Laeis P, Püchler K, Kirch W . The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction J Hypertens 2001 19 (Suppl): S21–S32
4. von Bergmann K et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil J Hypertens 2001 19 (Suppl): S33–S40
5. Püchler K, Nussberger J, Laeis P, Witte P-U . Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist in salt-restricted hypertensivepatients J Hypertens 1997 15: 1809–1812
Cited by 71 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis;International Journal of Clinical Pharmacy;2024-06-11
2. Area under the curve and ratio difference spectrophotometric methods with evaluation of the greenness for simultaneous determination of olmesartan medoxomil and metoprolol succinate;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2023-12
3. Nanotechnology‐Based Strategies for Extended‐Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review;Chemistry & Biodiversity;2023-11
4. A Prospective, Randomized Open-Label Study for Assessment of Antihypertensive Effect of Telmisartan Versus Cilnidipine Using Ambulatory Blood Pressure Monitoring (START ABPM Study);Cardiology Research;2023-06
5. A comprehensive review on invasomal carriers incorporating natural terpenes for augmented transdermal delivery;Future Journal of Pharmaceutical Sciences;2022-12-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3